Haematological malignancy (HM) histopathology
| All patients | HM after SLE | HM before/concurrent | ||||
|---|---|---|---|---|---|---|
| n | 45 | 29 | 16 | |||
| Hodgkin's lymphoma | 5 | (11%) | 3 | (10%) | 2 | (13%) |
| Indolent lymphoma | 9 | (20%) | 6 | (21%) | 3 | (19%) |
| DLBCL | 15 | (33%) | 13 | (45%) | 2 | (13%) |
| Burkitt's lymphoma | 1 | (2%) | 1 | (3%) | 0 | (0%) |
| T cell lymphoma | 4 | (9%) | 1 | (3%) | 3 | (19%) |
| Multiple myeloma | 2 | (4%) | 1 | (3%) | 1 | (6%) |
| Leukaemia/MPD/MDS | 9 | (20%) | 4 | (14%) | 5 | (31%) |
DLBCL, diffuse large B cell lymphoma; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; SLE, systemic lupus erythematosus.